C16:0 Sulfatide Inhibits Insulin Secretion in Rat β-Cells by Reducing the Sensitivity of KATP Channels to ATP Inhibition
- Karsten Buschard1,
- Maria Blomqvist2,
- Jan-Eric Månsson2,
- Pam Fredman2,
- Kirstine Juhl3 and
- Jesper Gromada4
- 1Bartholin Instituttet, Rigshospitalet, Copenhagen, Denmark
- 2Institute of Clinical Neuroscience, The Sahlgrenska Academy at Göteborg University, Mölndal Hospital, Mölndal, Sweden
- 3Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, Colorado
- 4Lilly Research Laboratories, Hamburg, Germany
- Address correspondence and reprint requests to Dr. Karsten Buschard, Bartholin Instituttet, Rigshospitalet, 2100 Copenhagen, Denmark. E-mail: buschard{at}dadlnet.dk
Abstract
Sulfatide (3′-sulfo-β-galactosyl ceramide) is a glycosphingolipid present in mammalians in various fatty acid isoforms of which the saturated 16 carbon-atom length (C16:0) is more abundant in pancreatic islets than in neural tissue, where long-chain sulfatide isoforms dominate. We previously reported that sulfatide isolated from pig brain inhibits glucose-induced insulin secretion by activation of ATP-sensitive K+ channels (KATP channels). Here, we show that C16:0 sulfatide is the active isoform. It inhibits glucose-stimulated insulin secretion by reducing the sensitivity of the KATP channels to ATP. (The half-maximal inhibitory concentration is 10.3 and 36.7 μmol/l in the absence and presence of C16:0 sulfatide, respectively.) C16:0 sulfatide increased whole-cell KATP currents at intermediate glucose levels and reduced the ability of glucose to induce membrane depolarization, reduced electrical activity, and increased the cytoplasmic free Ca2+ concentration. Recordings of cell capacitance revealed that C16:0 sulfatide increased Ca2+-induced exocytosis by 215%. This correlated with a stimulation of insulin secretion by C16:0 sulfatide in intact rat islets exposed to diazoxide and high K+. C24:0 sulfatide or the sulfatide precursor, β-galactosyl ceramide, did not affect any of the measured parameters. C16:0 sulfatide did not modulate glucagon secretion from intact rat islets. In βTC3 cells, sulfatide was expressed (mean [±SD] 0.30 ± 0.04 pmol/μg protein), and C16:0 sulfatide was found to be the dominant isoform. No expression of sulfatide was detected in αTC1-9 cells. We conclude that a major mechanism by which the predominant sulfatide isoform in β-cells, C16:0 sulfatide, inhibits glucose-induced insulin secretion is by reducing the KATP channel sensitivity to the ATP block.
- [Ca2+]i, cytoplasmic free Ca2+ concentration
- ELISA, enzyme-linked immunosorbent assay
- GalCer, galactosyl ceramide
- HPTLC, high-performance thin-layer chromatography
- KATP channel, ATP-sensitive K+ channel
- KRBH, Krebs-Ringer bicarbonate HEPES buffer
- PIP, phosphatidylinositol phosphate
- SulfLacCer, sulfated lactosyl ceramide
- TLC, thin-layer chromatography
Footnotes
-
J.G. is currently affiliated with Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
J.G. holds stock in Novo Nordisk.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Accepted July 5, 2006.
- Received October 18, 2005.
- DIABETES











